Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$19.08
$24.33M0.4123,223 shs237,144 shs
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$0.04
-2.4%
$0.03
$0.02
$0.06
$7.39M0.6230,686 shs49,425 shs
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$0.72
$0.72
$0.55
$1.45
$23.72M-0.57555,687 shsN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$0.05
-1.9%
$0.05
$0.02
$0.07
$20.82M-0.75111,147 shs230,462 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+8.46%+55.34%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
+3.80%+8.47%+57.69%+28.93%-21.90%
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
0.00%0.00%0.00%0.00%-47.78%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00%+13.79%-17.98%+4.21%+44.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.3517 of 5 stars
0.00.00.04.20.60.80.0
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00
N/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.00
N/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
2.33
Hold$0.9531.83% Upside
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$15.70M0.44N/AN/A$0.01 per share3.75
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$870.73K27.24N/AN/A$0.21 per share3.43
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$70K297.47$0.01 per share10.13$0.02 per share2.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
-$2.39MN/A0.00N/A-12.25%-89.43%-22.75%N/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
-$4.52M-$0.01N/AN/AN/A-14.16%-4.41%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.26
1.14
0.30
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/A
0.17
0.16
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/A
0.01
0.01

Institutional Ownership

CompanyInstitutional Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
68.55%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.10%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
3.80%
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
29.78%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
39.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
CV Sciences, Inc. stock logo
CVSI
CV Sciences
70184.79 million177.77 millionNot Optionable
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
932.92 million23.12 millionNo Data
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
20408.29 million248.16 millionNot Optionable

Recent News About These Companies

Oncotelic Therapeutics, Inc. (OTLC) - Yahoo Finance
Oncotelic Therapeutics Inc (OTLC)
Oncotelic Therapeutics Implements PDAOAI Platform
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
Russia faces new wave of drop in clinical trials for new drugs
Alibaba rises on report it will charge software service fee
ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

CV Sciences stock logo

CV Sciences OTCMKTS:CVSI

$0.04 0.00 (-2.44%)
As of 03:50 PM Eastern

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Cyclo Therapeutics stock logo

Cyclo Therapeutics NASDAQ:CYTH

$0.72 0.00 (0.00%)
As of 03/26/2025

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Oncotelic Therapeutics stock logo

Oncotelic Therapeutics OTCMKTS:OTLC

$0.05 0.00 (-1.92%)
As of 11:29 AM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.